Skip to main content

Mitch McConnell Directs DEA To Figure Out How To Distinguish Hemp From Marijuana

Senate Majority Leader Mitch McConnell (R-KY) inserted language into a spending bill on Thursday directing the Drug Enforcement Administration (DEA) to develop technology that can distinguish hemp from its “illicit cousin” marijuana.

The provision, which was attached to legislation to fund the Departments of Interior and Commerce for Fiscal Year 2020, is meant to support hemp manufacturers and regulators who must ensure that the crop is at or below a 0.3 percent THC content—the legal definition of hemp under the 2018 Farm Bill.

McConnell championed a measure in the wide-ranging agriculture legislation that federally legalized hemp and its derivatives, and he’s since devoted significant efforts to securing protections for the industry. For example, he backed provisions added to a separate appropriations bill last week that provides funding for the U.S. Department of Agriculture to implement hemp regulations.

“I stand ready to work with Kentucky’s hemp producers to address whatever challenges arise as they explore the full potential of this remarkable crop,” McConnell said of his latest provision. “Ensuring law enforcement can differentiate between industrial hemp and its illicit cousin is critical, and I’ll continue working with the DEA and other federal agencies so hemp can be treated the same as any other legal commodity.”

The measure, according to a McConnell press release, directs DEA to “to identify or develop on-the-spot field testing technologies” that would “enable law enforcement to distinguish between hemp and marijuana.”

DEA said in March that it was soliciting help to develop a device that can “provide specificity” in telling the cannabis cousins apart.

In May, McConnell also added language to a disaster relief funding bill clarifying that hemp farmers are entitled to federal crop insurance.

Besides his hemp-specific advocacy, the senator has pushed the Food and Drug Administration (FDA) to develop rules allowing one of the crop’s derivatives, CBD, to be marketed as a food item or dietary supplement.

He asked the head of the FDA in a letter this month to clear a path for the lawful marketing of CBD products, urging the department to issue enforcement discretion guidelines so that CBD businesses know FDA will only target seriously bad actors as it develops long-term regulations.

USDA Official Says There Are ‘Challenges’ Giving Hemp Farmers Insurance Coverage

Photo courtesy of Pixabay.

The post Mitch McConnell Directs DEA To Figure Out How To Distinguish Hemp From Marijuana appeared first on Marijuana Moment.

Original Article Source: https://www.marijuanamoment.net/mitch-mcconnell-directs-dea-to-figure-our-how-to-distinguish-hemp-from-marijuana/

Comments

Popular posts from this blog

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over  $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...